Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Nantong's IOVaxis Signs $103 Million Deal for RAS Cancer Vaccines

publication date: Jan 9, 2020

IOVaxis Therapeutics of Nantong acquired an option to in-license greater China rights for two Targovax mutant RAS therapeutic vaccines, TG01 and TG02. If the option is exercised, IOVaxis will pay $3 million upfront for the license and Targovax, a Norwegen company, will be eligible for up to $100 million in milestones, plus double digit royalties. RAS mutations are found in over 90% of pancreatic cancer cases, 50% of colorectal cancer and 20-30% of all cancers. Targovax expects its vaccines will induce T-cell immune responses in cancer patients with RAS mutations. More details....

Stock Symbol: (OSE: TRVX)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital